medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (1)

Survival of adult patients with non-promyelocytic acute myeloid leukemia treated with high doses of anthracyclines

Quintero SY, Concepción FY, Hernández PC, Romero GA, Macia PI, Lam RM

Language: Spanish
References: 14
Page: 1-15
PDF size: 685.56 Kb.


ABSTRACT

Introduction: Acute myeloid leukemia is a heterogeneous disease characterized by the clonal expansion of undifferentiated precursors that causes bone marrow failure.
Objective: To analyze the survival of adult patients with non-promyelocytic acute myeloid leukemia treated with high doses of induced anthracyclines at induction.
Methods: An analytical, retrospective and longitudinal study was carried out with 53 adult patients younger than 60 years, treated at the Institute of Hematology and Immunology, from September 2013 to December 2018. These patients had a diagnosis of nonpromyelocytic acute myeloid leukemia and received high doses of anthracyclines (daunoribicin) under induction therapy.
Results: The probabilities of overall survival at 12 months were higher for the group of 19- 29 years, accounting for 59%, and lower for the group of 40-49 years, accounting for 21%. In the age group of 19-29 years, the probability of event-free survival was 65% and the probability of disease-free survival was 44%. In the group of 40-49 years, it decreased to 27%; while in the group of 50-59 it increased, reaching 80%. Regarding overall survival associated with the rearranged genes, it was higher for the patients who had the NPM1 and AML1-ETO genes and lower for those who had the FLT3 and BCR/ABL genes.
Conclusions: Age groups and genetic alterations do not modify the survival of patients with non-promyelocytic acute myeloid leukemias treated with high doses of anthracyclines.


REFERENCES

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405.

  2. National Cancer Institute. Cancer Statistics. Epidemiology and End Results (SEER) Program of the National Cancer Institute. [acceso 26/01/2019]Disponible en: http://seer.cancer.gov/csr

  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Myeloid Leukemia Version 1.2017. February 24, 2017 [acceso 18/12/2019]. Disponible en: https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf

  4. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-21.

  5. Castaigne S, Chevret S, Archimbaud E. Randomized comparison of double induction and timed-sequential induction to a “3+7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104:2467-74.

  6. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

  7. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline Dose Intensification in Acute Myeloid Leukemia. N Engl J Med 2009;361:1249–59. doi:10.1056/NEJMoa0904544

  8. Li X, Xu S, Tan Y, Chen J. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. Cochrane Database of Systematic Reviews. 2015;6(CD010432). doi: 10.1002/14651858.CD010432.pub2

  9. Hernández C, Núñez A, Rodríguez Y, Carnot J, Chávez R, Moya I. Primer caso de leucemia mieloide aguda tratado en Cuba con altas dosis de antraciclinas en la inducción. Rev Cub Med. 2012 Jun [acceso 18/12/2019];51( 2 ):197-204. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003475232012000200011&lng=es.

  10. Quintero Y, Hernández C, Romero A, Concepción Y, Macia I, Llerena D et al. Incorporación de las altas dosis de antraciclina en el tratamiento de la leucemia mieloide aguda del adulto. Rev Cub Hematol Inmunol Hemoter. 2019 [acceso 18/12/2019];35(1):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/942

  11. Gong Q, Zhou L, Xu Sh, Li X, Zou Y, Chen J, et al. High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials. Blood. 2016 Mar 24;127(12):1551-8. doi: 10.1182/blood-2015-07-657403.

  12. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLOS ONE. 2013 Apr 5 [acceso 18/12/2019];8(4):e60699. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060699

  13. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832-41. doi:10.1182/blood-2011-06-361410

  14. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and metaanalysis. Br J Haematol. 2013;161:192-203. doi: 10.1111/bjh.12233




2020     |     www.medigraphic.com